Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225

Abstract
Background C225 is an antibody to the epidermal growth factor receptor (EGFR), and inhibits growth of various tumour cells. The antibody is currently being used as a therapeutic agent in several cli...

This publication has 35 references indexed in Scilit: